Summers KM, Kockler DR. Rituximab treatment of refractory rheumatoid arthritis. Ann Pharmacother. 2005;39:2091–5. https://doi.org/10.1345/aph.1G311.

Article  CAS  PubMed  Google Scholar 

KDIGO. Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;2024(105):S1-69. https://doi.org/10.1016/j.kint.2023.09.002.

Article  Google Scholar 

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45. https://doi.org/10.1136/annrheumdis-2019-215089.

Article  CAS  PubMed  Google Scholar 

Chen P, Zhou Y, Wu L, Chen S, Han F. Efficacy and safety of biologic agents for lupus nephritis: a systematic review and meta-analysis. J Clin Rheumatol. 2023;29:95–100. https://doi.org/10.1097/RHU.0000000000001877.

Article  PubMed  Google Scholar 

KDIGO 2024 Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22–33. https://doi.org/10.4161/mabs.22771.

Article  PubMed  PubMed Central  Google Scholar 

Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. B cell trophic factors and B cell antagonism in autoimmune disease. 8. 2005.

Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118:358–67. https://doi.org/10.1182/blood-2010-09-305847.

Article  CAS  PubMed  Google Scholar 

Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood. 2017;130:581–9. https://doi.org/10.1182/blood-2017-03-771832.

Article  CAS  PubMed  Google Scholar 

Smith KGC, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:328–43. https://doi.org/10.1038/nri2762.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118:2530–40. https://doi.org/10.1182/blood-2011-01-330357.

Article  PubMed  Google Scholar 

Schieber T, Li A, Lundberg J, Wiczer T, Voorhees T. Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders. Blood Adv. 2023;7:3431–4. https://doi.org/10.1182/bloodadvances.2022009548.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teeling JL, Mackus WJM, Wiegman LJJM, Van Den Brakel JHN, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 1. pp. 177. 2006.

Beers SA, French RR, Chan HTC, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191–201. https://doi.org/10.1182/blood-2010-01-263533.

Article  CAS  PubMed  Google Scholar 

Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009;46:2419–23. https://doi.org/10.1016/j.molimm.2009.04.009.

Article  CAS  PubMed  Google Scholar 

Johnson NA, Leach S, Woolcock B, Deleeuw RJ, Bashashati A, Sehn LH, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica. 2009;94(3):423–7. https://doi.org/10.3324/haematol.2008.001024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003. https://doi.org/10.1182/blood-2002.

Article  PubMed  Google Scholar 

Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738–43. https://doi.org/10.1182/blood-2003-06-2031.

Article  CAS  PubMed  Google Scholar 

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, et al. Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. J Immunol. 2016;197:1762–75. https://doi.org/10.4049/jimmunol.1600648.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell - mediated B-cell cytotoxicity. Blood. 2010;115:4393–402. https://doi.org/10.1182/blood-2009-06-225979.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117:4519–29. https://doi.org/10.1182/blood-2010-07-296913.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Illidge TM, Cheadle EJ, Honeychurch J. New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor. Leuk Lymphoma. 2014;55:3–4. https://doi.org/10.3109/10428194.2013.797976.

Article  PubMed  Google Scholar 

Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367:1224–30. https://doi.org/10.1126/science.aaz9356.

Article  CAS  PubMed  Google Scholar 

Kumar A, Planchais C, Fronzes R, Mouquet H, Reyes N. Binding mechanisms of therapeutic antibodies to human CD20 Downloaded from. 2020.

Gagez AL, Cartron G. Obinutuzumab: A new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 2014;26:484–91. https://doi.org/10.1097/CCO.0000000000000107.

Article  CAS  PubMed  Google Scholar 

Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. Baff mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000. https://doi.org/10.1084/jem.192.10.1453.

Article  PubMed  PubMed Central  Google Scholar 

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood. 2002. https://doi.org/10.1182/blood.V99.3.754.

Article  PubMed  Google Scholar 

Könitzer JD, Sieron A, Wacker A, Enenkel B. Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0145633.

Article  PubMed  PubMed Central  Google Scholar 

Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012–24. https://doi.org/10.1177/0091270009337512.

Article  CAS  PubMed  Google Scholar 

Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182:29–45. https://doi.org/10.1111/bjh.15232.

Article  PubMed  Google Scholar 

Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol. 2021;32:2652–63. https://doi.org/10.1681/ASN.2021040561.

Article  CAS  PubMed  PubMed Central